Reading this on a mobile device? Try our optimized mobile version here:

December 4, 2012
Sign upForwardArchive
News for the PBM Industry

  Featured Stories 
  • Generic-drug-makers retool as patent cliff wanes
    Opportunities are drying up for makers of generic drugs as the value of treatments set to lose patent protection and be sold as generics is anticipated to drop by more than half in 2013 to around $17 billion, a Crédit Agricole Securities analysis found. Many makers of generics are trying to adapt through acquisitions, branded products or treatments that are hard to produce. The New York Times (tiered subscription model) (12/3) LinkedInFacebookTwitterEmail this Story
 Registration is now open for PCMA's Managed Markets Educational Forum!
Whether you are a seasoned managed markets executive or someone who supports the team, PCMA's Managed Markets Educational Forum will provide valuable education on fundamental, as well as complex and strategic issues relevant to professionals of all levels within pharma managed markets or market access divisions. Visit PCMA's website to learn more about our 2013 events!

  Legislative & Regulatory News 
  • Republicans include Medicare, Social Security cuts in fiscal cliff talks
    House Republicans made a fiscal cliff counteroffer to President Barack Obama worth $2.2 trillion, calling for bringing in $800 billion in additional tax revenue by closing loopholes and deductions, reducing cost-of-living increases for Social Security benefits and raising the eligibility age for Medicare. The proposal is in response to Obama's plan to increase taxes by $1.6 trillion in the next 10 years without subjecting Social Security and Medicare to budget cuts. The Washington Post/The Associated Press (12/4) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Report: Drugmakers improve R&D productivity, but challenges remain
    Drugmakers are taking a targeted, smarter approach to research and development, getting more compounds through the approval process, but nagging commercialization issues remain, according to a Deloitte and Thomson Reuters report. The number of new drug approvals was up by about 30%, according to the annual report, but expected revenue from new drugs was lower. The average cost of developing a new drug hovered around $1.1 billion. Reuters (12/3) LinkedInFacebookTwitterEmail this Story
  Opinion, Commentary & Analysis 
It is astonishing what force, purity and wisdom it requires for a human being to keep clear of falsehoods."
--Margaret Fuller,
American journalist and women's rights activist


Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information